Skip to content
Disclosery

GREAT POINT PARTNERS LLC

Follow

13F filer, CIK 1281446, Greenwich, CT

GREAT POINT PARTNERS LLC reported $529,120,900 across 42 holdings for the quarter ended 2026-06-30, in a 13F-HR filed 2026-08-14. Its ten largest share positions make up 53.65% of the portfolio.

Filed (acceptance time not in the bulk data set), ingested 13F-HR 0001172661-26-003750

Period
2026-06-30
Reported value
$529M
Holdings
42
Top 10 weight
53.65%
New
13
Sold out
13

Largest buys vs the previous quarter

SecurityShares changeApprox. value
ABVXnew+204,314$27.2M
DFTXnew+425,000$20M
VERAadded+401,488$17.2M
SGMTnew+2,029,933$15.7M
IMMXadded+927,642$9.56M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Largest sells vs the previous quarter

SecurityShares changeApprox. value
APGEexited-374,000-$31.5M
AMLXreduced-1,050,000-$18.9M
KALVexited-675,000-$13.6M
IMVTexited-545,625-$13.6M
JBIOexited-964,462-$13.6M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Holdings, Q2 2026

Share positions as resolved from 13F-HR 0001172661-26-003750, largest first. % of portfolio is the value over $424,448,729, the sum of the share positions whose value is usable for ratios (method).

SecurityHistorySharesValue% of portfolioChangeLatest eventTimeline
VORVOR BIOPHARMA INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 1,370,107 shares; 2026Q1: 1,750,000 shares; 2026Q2: 1,700,000 shares 1,700,000$31.3M7.37%-50,000Timeline
ABVXABIVAX SAQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: 2,128,773 shares; 2024Q4: 1,648,523 shares; 2025Q1: 1,638,111 shares; 2025Q2: 1,291,617 shares; 2025Q3: 150,000 shares; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: 204,314 shares 204,314$27.2M6.41%newTimeline
VERAVERA THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 199,348 shares; 2026Q2: 600,836 shares 600,836$25.8M6.07%+401,488Timeline
ZURAZURA BIO LTDQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: 3,263,672 shares; 2024Q4: 3,170,194 shares; 2025Q1: 3,170,194 shares; 2025Q2: 3,170,194 shares; 2025Q3: 3,815,930 shares; 2025Q4: 3,815,930 shares; 2026Q1: 4,215,930 shares; 2026Q2: 4,215,930 shares 4,215,930$24.9M5.86%0Timeline
ALMSALUMIS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 856,061 shares; 2026Q2: 856,061 shares 856,061$24.1M5.68%0Timeline
SLGLSOL-GEL TECHNOLOGIES LTDQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 274,363 shares; 2026Q2: 274,363 shares 274,363$20.3M4.79%0Timeline
DFTXDEFINIUM THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: 425,000 shares 425,000$20M4.71%newTimeline
ANNXANNEXON INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 2,500,000 shares; 2026Q2: 3,500,000 shares 3,500,000$20M4.71%+1,000,000Timeline
ORKAORUKA THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: 514,659 shares; 2024Q4: 228,803 shares; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: 183,330 shares; 2025Q4: 183,330 shares; 2026Q1: 183,330 shares; 2026Q2: 183,330 shares 183,330$17.4M4.11%0Timeline
MLTXMOONLAKE IMMUNOTHERAPEUTICSQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 500,000 shares; 2026Q2: 855,813 shares 855,813$16.7M3.93%+355,813Timeline
SGMTSAGIMET BIOSCIENCES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: 2,029,933 shares 2,029,933$15.7M3.7%newTimeline
CTNMCONTINEUM THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 800,000 shares; 2026Q1: 800,198 shares; 2026Q2: 921,481 shares 921,481$15.1M3.56%+121,283Timeline
IMMXIMMIX BIOPHARMA INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 350,000 shares; 2026Q2: 1,277,642 shares 1,277,642$13.2M3.1%+927,642Timeline
CLYMCLIMB BIO INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: 248,168 shares; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 979,534 shares; 2026Q1: 1,334,130 shares; 2026Q2: 1,000,000 shares 1,000,000$13M3.07%-334,130Timeline
AMLXAMYLYX PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: 1,811,996 shares; 2025Q2: 2,000,000 shares; 2025Q3: 1,700,000 shares; 2025Q4: 1,750,000 shares; 2026Q1: 1,750,000 shares; 2026Q2: 700,000 shares 700,000$12.6M2.96%-1,050,000Timeline
NKTRNEKTAR THERAPEUTICSQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: 300,000 shares; 2025Q4: 210,732 shares; 2026Q1: 316,453 shares; 2026Q2: 175,000 shares 175,000$12.2M2.88%-141,453Timeline
NGNENEUROGENE INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: 1,004,291 shares; 2024Q4: 442,761 shares; 2025Q1: 470,964 shares; 2025Q2: 485,859 shares; 2025Q3: 446,814 shares; 2025Q4: 350,000 shares; 2026Q1: 500,000 shares; 2026Q2: 352,180 shares 352,180$11.1M2.61%-147,820Timeline
LBRXLB PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 300,000 shares; 2026Q2: 317,221 shares 317,221$10.3M2.43%+17,221Timeline
IRDOPUS GENETICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 324,340 shares; 2026Q2: 1,970,187 shares 1,970,187$8.1M1.91%+1,645,847Timeline
EPRXEUPRAXIA PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: 1,200,000 shares; 2025Q4: 1,200,000 shares; 2026Q1: 1,200,000 shares; 2026Q2: 1,200,000 shares 1,200,000$7.93M1.87%0Timeline
DRUGBRIGHT MINDS BIOSCIENCES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 220,000 shares; 2026Q2: 109,603 shares 109,603$7.69M1.81%-110,397Timeline
IFRXINFLARX NVQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: 3,046,557 shares 3,046,557$6.82M1.61%newTimeline
RLMDRELMADA THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 842,106 shares; 2026Q2: 842,106 shares 842,106$5.83M1.37%0Timeline
JATTJATT II ACQUISITION CORPQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: 500,000 shares 500,000$5.68M1.34%newTimeline
CGEMCULLINAN THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 634,032 shares; 2026Q1: 300,000 shares; 2026Q2: 300,000 shares 300,000$5.46M1.29%0Timeline
ALTALTIMMUNE INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: 1,741,232 shares 1,741,232$5.29M1.25%newTimeline
AMANAMANAT ACQUISITION CORPQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: 500,000 shares 500,000$5.08M1.2%newTimeline
RZLTREZOLUTE INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: 621,894 shares; 2025Q1: 833,042 shares; 2025Q2: 3,033,462 shares; 2025Q3: 2,451,809 shares; 2025Q4: 951,809 shares; 2026Q1: 951,809 shares; 2026Q2: 951,809 shares 951,809$4.95M1.17%0Timeline
SLNSILENCE THERAPEUTICS PLCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 808,032 shares; 2026Q1: 1,020,489 shares; 2026Q2: 450,000 shares 450,000$4.94M1.16%-570,489Timeline
PALIPALISADE BIO INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 3,405,757 shares; 2026Q2: 2,284,819 shares 2,284,819$4.78M1.13%-1,120,938Timeline
EVMNEVOMMUNE INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 325,000 shares; 2026Q1: 325,000 shares; 2026Q2: 325,000 shares 325,000$4.32M1.02%0Timeline
SCYXSCYNEXIS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: 944,292 shares 944,292$3.84M0.91%newTimeline
ELVNENLIVEN THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: 70,000 shares 70,000$3.55M0.84%newTimeline
HUMAHUMACYTE INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 3,750,000 shares; 2026Q2: 3,750,000 shares 3,750,000$2.93M0.69%0Timeline
RNTXREIN THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: 2,575,000 shares 2,575,000$2.68M0.63%newTimeline
DBVTDBV TECHNOLOGIES S AQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: 374,679 shares; 2025Q3: 378,594 shares; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: 156,906 shares 156,906$2.57M0.61%newTimeline
PMNPROMIS NEUROSCIENCES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 371,402 shares; 2026Q2: 86,150 shares 86,150$1.13M0.27%-285,252Timeline

Options

Puts and calls, as filed. The amount and value describe the underlying shares, not the option premium, so they stay out of % of portfolio (H5).

SecurityTypeAmountValueChange
ABVXABIVAX SA SPONSORED ADScall400,000$53.3Mnew
IBRXIMMUNITYBIO INC COMput3,000,800$26.3M0
RAREULTRAGENYX PHARMACEUTICAL IN COMput600,000$20Mnew
GALTGALECTIN THERAPEUTICS INC COMMON STOCKcall800,000$3.71M0
AVXLANAVEX LIFE SCIENCES CORP COM NEWcall521,300$1.35M0

Sold out in Q2 2026

Positions in the previous quarter's report that this quarter's report no longer lists.

SecurityShares beforeValue beforeType
APGEAPOGEE THERAPEUTICS INC374,000$31.5Mshares
KALVKALVISTA PHARMACEUTICALS INC675,000$13.6Mshares
IMVTIMMUNOVANT INC545,625$13.6Mshares
JBIOJADE BIOSCIENCES INC964,462$13.6Mshares
ZBIOZENAS BIOPHARMA INC524,066$10.2Mshares
CMPXCOMPASS THERAPEUTICS INC1,350,000$7.14Mshares
SCYXSCYNEXIS INC7,554,347$6.93Mshares
CNTXCONTEXT THERAPEUTICS INC2,238,496$5.86Mshares
UNCYUNICYCIVE THERAPEUTICS INC796,558$5.24Mshares
TENXTENAX THERAPEUTICS INC327,307$5.23Mshares
PHVSPHARVARIS N V82,800$2.34Mshares
AVTXAVALO THERAPEUTICS INC124,666$1.86Mshares
ALKSALKERMES PLC50,000$1.77Mshares

How Q2 2026 was built

Available 13F filings of this filer for the quarter and their roles: the base report is the latest original or restatement, NEW HOLDINGS amendments filed after it are added (method).

FilingRoleAmendmentFiledAcceptedIngested
13F-HR 0001172661-26-003750 base2026-08-14acceptance time not in the bulk data set

Filings

Every filing of this filer: 13F reports and notices, the 13D and 13G it filed or is a reporting person of, and Forms 3, 4 and 5 it reported as an owner.

FilingSubjectFiledAcceptedIngested
13F-HR 0001172661-26-003750 Quarter ended 2026-06-302026-08-14acceptance time not in the bulk data set
13F-HR 0001172661-26-002272 Quarter ended 2026-03-312026-05-15acceptance time not in the bulk data set
13F-HR 0001172661-26-001093 Quarter ended 2025-12-312026-02-17acceptance time not in the bulk data set
13F-HR 0001814554-25-000164 Quarter ended 2025-09-302025-11-14acceptance time not in the bulk data set
13F-HR 0001172661-25-003478 Quarter ended 2025-06-302025-08-14acceptance time not in the bulk data set
13F-HR 0001172661-25-002331 Quarter ended 2025-03-312025-05-15acceptance time not in the bulk data set
13F-HR 0001172661-25-001157 Quarter ended 2024-12-312025-02-14acceptance time not in the bulk data set
13F-HR 0001172661-24-004656 Quarter ended 2024-09-302024-11-13acceptance time not in the bulk data set
13F-HR 0001172661-24-003577 Quarter ended 2024-06-302024-08-14acceptance time not in the bulk data set
13F-HR 0001172661-24-002523 Quarter ended 2024-03-312024-05-15acceptance time not in the bulk data set
13F-HR 0001172661-24-001436 Quarter ended 2023-12-312024-02-14acceptance time not in the bulk data set
13F-HR 0001172661-23-004025 Quarter ended 2023-09-302023-11-14acceptance time not in the bulk data set
13F-HR 0001172661-23-003165 Quarter ended 2023-06-302023-08-14acceptance time not in the bulk data set
13F-HR 0001172661-23-002293 Quarter ended 2023-03-312023-05-15acceptance time not in the bulk data set
13F-HR 0001172661-23-001300 Quarter ended 2022-12-312023-02-14acceptance time not in the bulk data set
13F-HR 0001172661-22-002573 Quarter ended 2022-09-302022-11-14acceptance time not in the bulk data set
13F-HR 0001172661-22-001993 Quarter ended 2022-06-302022-08-15acceptance time not in the bulk data set
13F-HR 0001172661-22-001465 Quarter ended 2022-03-312022-05-16acceptance time not in the bulk data set
13F-HR 0001172661-22-000487 Quarter ended 2021-12-312022-02-14acceptance time not in the bulk data set
13F-HR 0001172661-21-002382 Quarter ended 2021-09-302021-11-15acceptance time not in the bulk data set
13F-HR 0001172661-21-001868 Quarter ended 2021-06-302021-08-16acceptance time not in the bulk data set
13F-HR 0001172661-21-001313 Quarter ended 2021-03-312021-05-17acceptance time not in the bulk data set
13F-HR 0001172661-21-000726 Quarter ended 2020-12-312021-02-16acceptance time not in the bulk data set
13F-HR 0001172661-20-002326 Quarter ended 2020-09-302020-11-16acceptance time not in the bulk data set
13F-HR 0001172661-20-001861 Quarter ended 2020-06-302020-08-14acceptance time not in the bulk data set
13F-HR 0001172661-20-001361 Quarter ended 2020-03-312020-05-15acceptance time not in the bulk data set
13F-HR 0001172661-20-000830 Quarter ended 2019-12-312020-02-14acceptance time not in the bulk data set
13F-HR 0000930413-19-002849 Quarter ended 2019-09-302019-11-15acceptance time not in the bulk data set
13F-HR 0000930413-19-002313 Quarter ended 2019-06-302019-08-14acceptance time not in the bulk data set
13F-HR 0000930413-19-001676 Quarter ended 2019-03-312019-05-14acceptance time not in the bulk data set
13F-HR 0000930413-19-000592 Quarter ended 2018-12-312019-02-15acceptance time not in the bulk data set
13F-HR 0000930413-18-003323 Quarter ended 2018-09-302018-11-14acceptance time not in the bulk data set
13F-HR 0000930413-18-002592 Quarter ended 2018-06-302018-08-14acceptance time not in the bulk data set
13F-HR 0000930413-18-001815 Quarter ended 2018-03-312018-05-14acceptance time not in the bulk data set
13F-HR 0000930413-18-000474 Quarter ended 2017-12-312018-02-14acceptance time not in the bulk data set
13F-HR 0000930413-17-003778 Quarter ended 2017-09-302017-11-14acceptance time not in the bulk data set
13F-HR 0000930413-17-002918 Quarter ended 2017-06-302017-08-14acceptance time not in the bulk data set
13F-HR 0000930413-17-002121 Quarter ended 2017-03-312017-05-15acceptance time not in the bulk data set
13F-HR 0000930413-17-000546 Quarter ended 2016-12-312017-02-14acceptance time not in the bulk data set
13F-HR 0000930413-16-008703 Quarter ended 2016-09-302016-11-14acceptance time not in the bulk data set
13F-HR 0000930413-16-007885 Quarter ended 2016-06-302016-08-15acceptance time not in the bulk data set
13F-HR 0000930413-16-007144 Quarter ended 2016-03-312016-05-16acceptance time not in the bulk data set
13F-HR 0000930413-16-005528 Quarter ended 2015-12-312016-02-16acceptance time not in the bulk data set
13F-HR 0000930413-15-004329 Quarter ended 2015-09-302015-11-16acceptance time not in the bulk data set
13F-HR 0000930413-15-003355 Quarter ended 2015-06-302015-08-14acceptance time not in the bulk data set
13F-HR 0000930413-15-002517 Quarter ended 2015-03-312015-05-15acceptance time not in the bulk data set
13F-HR 0000930413-15-000640 Quarter ended 2014-12-312015-02-17acceptance time not in the bulk data set
13F-HR 0000930413-14-004572 Quarter ended 2014-09-302014-11-14acceptance time not in the bulk data set
13F-HR 0000930413-14-003671 Quarter ended 2014-06-302014-08-14acceptance time not in the bulk data set
13F-HR 0000930413-14-002534 Quarter ended 2014-03-312014-05-15acceptance time not in the bulk data set
13F-HR 0000930413-14-000601 Quarter ended 2013-12-312014-02-14acceptance time not in the bulk data set
13F-HR 0000930413-13-005397 Quarter ended 2013-09-302013-11-14acceptance time not in the bulk data set
13F-NT 0000930413-13-004245 Quarter ended 2013-06-302013-08-14acceptance time not in the bulk data set